Medtronic (NYSE: MDT) stock slipped 2.8% through 10:15 a.m. ET this morning despite beating earnings forecasts in its fiscal Q4 2024 earnings report.
Heading into earnings, analysts had the medical devices company pegged for a $1.45 per-share profit, but Medtronic “beat” by a penny, reporting $1.46 instead. Similarly, Medtronic exceeded expectations for $8.4 billion in sales by reporting $8.6 billion.
And yet the shares are down today. Why?
Medtronic Q1 earnings
Well, earnings beats are of course wonderful, but not all Medtronic’s news was good. Q4 sales that exceeded expectations still only grew about 0.5% year over year. And while Medtronic claimed a $1.46 profit, it turns out that was only if you don’t count costs that Medtronic considers one-time in nature. When calculated according to generally accepted accounting principles (GAAP), Medtronic actually earned only $0.49 per share — down 44% year over year.
I think you’ll agree: This is much less impressive.
Is Medtronic stock a sell?
On the plus side, Medtronic’s full-year fiscal 2024 results were stronger. Sales for the full fiscal year grew a respectable 4% to $32.4 billion, and earnings were down only 2%. Medtronic earned a $2.76 per-share GAAP profit for the year.
Can Medtronic do better than that in fiscal 2025 (i.e., this coming year)? Actually, it might.
Turning to guidance, Medtronic management forecast sales growth of between 3% and 4% this coming year, so at least $33.4 billion. That’s about what Wall Street was already expecting. Similarly, earnings guidance for 4% to 5% growth to about $5.45 per share, non-GAAP, was only in line with expectations.
And that right there is Medtronic’s problem. Yes, Medtronic beat earnings in fiscal 2024, but at a valuation of 27 times earnings, that was probably the bare minimum the company needed to do. To keep its 27x earnings valuation, though, Medtronic also needed to promise strong growth in the year ahead — and Medtronic failed to do that.
Conclusion: Medtronic stock clearly costs too much. That’s why investors are selling.
Should you invest $1,000 in Medtronic right now?
Before you buy stock in Medtronic, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medtronic wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $581,764!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of May 13, 2024
Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.
Why Medtronic Stock Slumped Today was originally published by The Motley Fool
Signup bonus from
